Consort Medical unveils new Corporate Group website – A single source supply chain solution for drug and delivery device manufacturing services
This business model has been brought to the market following Consort Medical’s acquisition of Aesica. Consort Medical combined and integrated Aesica’s drug formulation, manufacturing and packaging capabilities with Bespak’s delivery device development and manufacturing services. This has created a global single source drug and device contract manufacturing partner for pharmaceutical customers. The full range of services that the Group provides includes finished dose manufacturing, formulation development, API development and manufacture for drugs, together with pilot to high volume manufacturing, prototype development and design for manufacture and concept generation for drug delivery devices.
Aesica and Bespak have strong synergies and similarities across quality control, regulatory compliance and reliable manufacturing. This includes QP release and ISO certified Quality Management Systems, cGMP compliance and operating to FDA and MHRA standards of approval. Furthermore, both companies comply with environmental and health and safety standards. Aesica provides secure facilities that handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level, whilst Bespak is accredited with ISO 14001.
Both companies provide pilot up to volume manufacturing – operating at scales from grams to full scale manufacture of drugs and low hand machine production through to high volume device assembly. In addition, continuous improvement tools underpin each company’s operations. Moreover, Aesica and Bespak offer complex solutions and capabilities ranging from semi continuous processing, high capacity and high potent drug manufacturing through to 6-Sigma quality on high volume components and devices.